iBio

iBio, Inc. is a biotechnology company, which engages in the development and manufacture of biotherapeutics. It operates through the Biopharmaceuticals and Bioprocessing segments. The Biopharmaceuticals segment involves molecule discovery, development, and licensing activities. The Bioprocessing segment includes contract development and manufacturing services for recombinant proteins. The company was founded on April 17, 2008 and is headquartered in Bryan, TX.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q1 2025

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

iBio, Inc. is an AI-driven innovator that develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard to target cancers, and other diseases. It focuses on decreasing drug failures, shortening drug development timelines and opening up new frontiers against the most promising targets. The company was founded on April 17, 2008 and is headquartered in San Diego, CA.

IBIO stock may have missed out on the success of larger vaccine makers, but it's hoping the omicron variant will change that. The post IBIO Stock Surges as the Biotech Company Looks to Leverage Omicron Fears appeared first on InvestorPlace.

IBIO Stock Surges as the Biotech Company Looks to Leverage Omicron Fears

iBio Inc (NYSE: IBIO) announced an update for its lead COVID-19 vaccine program, IBIO-202, in light of the emergence of the Omicron (B.1.1.529) variant of SARS-CoV-2. Last week, the World Health Organization's (WHO) Technical Advisory Group on SARS-CoV-2 Virus Evolution classified Omicron as a Variant of Concern.

In Light Of Omicron Variant, iBio Issues Update For IBIO-202 COVID-19 Program

Diffusion Pharmaceuticals

Leap Therapeutics

Check these three biotech penny stocks out for your list this month The post Hot Biotech Penny Stocks to Watch As New Variant Creates Volatility appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Biotech Penny Stocks to Watch As New Variant Creates Volatility

- Global Reliance on Spike Protein-Based Vaccines May Create Public Health Risks -

Omicron Variant Underscores Need for New COVID Vaccine Candidates Like IBIO-202

Chembio Diagnostics

Geovax Labs

NovaBay Pharmaceuticals

Oragenics

SINTX Technologies Inc

XpresSpa Group

Hot penny stocks to watch as new virus fears emerge on Black Friday. The post Hot Penny Stocks To Buy?

Hot Penny Stocks To Buy? 7 To Watch As African Variant Shakes Markets

BRYAN, Texas, Nov. 17, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System®, announced today that Glass Lewis and Co., LLC (“Glass Lewis”), a leading independent provider of proxy research and vote recommendations to the investment community, has recommended that the Company's stockholders vote “FOR” all proposals put forth in the definitive proxy statement prior to its Annual Meeting of Stockholders to be held on December 9, 2021.

Leading Independent Proxy Advisory Firm, Glass Lewis, Recommends iBio Shareholders Vote “FOR” All Proposals Ahead of Annual Meeting

- Adds First New Anti-cancer Target for Development in Partnership with RubrYc Therapeutics -

iBio Reports Fiscal First Quarter 2022 Financial Results and Provides Corporate Update

BRYAN, Texas, Nov. 15, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming Manufacturing System®, today announced a research collaboration with the University of Texas Southwestern Medical Center (“UT Southwestern”) to explore in solid tumors the anti-cancer potential of the molecule that is part of the IBIO-100 program.

iBio Announces Collaboration with UT Southwestern to Investigate IBIO-100 in Solid Tumors

BRYAN, Texas, Nov. 08, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System®, announced today that it will report its fiscal 2022 first quarter financial results after market close on Monday, November 15, 2021. iBio management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.

iBio to Report Fiscal 2022 First Quarter Financial Results and Provide Corporate Update on Monday, November 15, 2021

Invesco Mortgage Capital

Cenntro Electric Group

PBF Energy

SNDL Inc.

Electrameccanica

Investing in penny stocks is always fraught with risk. However, these companies have dubious business models making them even riskier.

6 Penny Stocks to Part With Before They Crash and Burn

- Takes Sole Ownership of CDMO Subsidiary & U.S. Manufacturing Rights -

iBio Acquires FastPharming Manufacturing Facility®

BRYAN, Texas, Oct. 26, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System®, today urged its stockholders to vote “FOR” all proposals put forth in the proxy statement prior to the Company's December 9, 2021 Annual Meeting of Stockholders.

iBio Urges Shareholders to Vote “FOR” All Proposals Ahead of its Upcoming Annual Meeting to be Held on December 9

Cinedigm

China Rapid Finance

Looking for penny stocks to buy with high-momentum right now? Check these three out for your list The post Hot Penny Stocks to Watch That You Might've Missed This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Penny Stocks to Watch That You Might've Missed This Week

Pre-clinical successes lead to exclusive licensing agreements for iBio.

This Under-the-Radar Pharma Company Could Be a Bargain Hunter's Dream

iBio, Inc. (IBIO) CEO Thomas Isett on Q4 Fiscal 2021 Results - Earnings Call Transcript

Expanded Immuno-Oncology Pipeline with License of Next-Gen anti-CD25 Antibody for Solid Tumors

iBio Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Corporate Update

BRYAN, Texas, Sept. 20, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System®, today announced that the Company's Chairman & CEO, Tom Isett, and its CSO, Martin Brenner, DVM, Ph.D., will participate in a fireside chat at the Cantor Virtual Global Healthcare Conference on Monday, September 27, 2021 at 10:00 a.m. Eastern Time.

iBio to Participate in the Cantor 2021 Virtual Global Healthcare Conference

BRYAN, Texas, Sept. 20, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System®, announced today that it will report its fiscal fourth quarter and full year 2021 financial results before market open on Monday, September 27, 2021. iBio management will host a webcast and conference call at 8:30 a.m. Eastern Time to discuss the results and provide a corporate update.

iBio to Report Fiscal Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update on Monday, September 27, 2021

Sphere 3D

Vinco Ventures

Genius Brands

Uranium Energy

Meme stocks have enjoyed another recent surge. However, don't get caught holding the bag with these seven less promising ones.

7 Meme Stocks to Sell Before They Go to $0

BRYAN, Texas, Sept. 07, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System®, today announced that it will participate in the H.C. Wainwright 23rd Annual Global Investment Conference, to be held virtually September 13-15, 2021.

iBio Announces Participation in H.C. Wainwright 23rd Annual Global Investment Conference

Industry veteran adds deep expertise in immuno-oncology to the Board Industry veteran adds deep expertise in immuno-oncology to the Board

iBio Appoints William D. Clark to its Board of Directors

iBio Inc (NYSE: IBIO) has signed an exclusive license agreement with RubrYc Therapeutics Inc for RTX-003, an immunotherapy candidate targeting regulatory T cells (Tregs).  Related: IBio Adds Three Cancer Antibody Programs.

iBio Expands Immuno-Oncology Pipeline With RubrYc Deal

– iBio licenses a novel antibody targeting regulatory T cells –

iBio Expands Immuno-Oncology Pipeline in AI Partnership with RubrYc Therapeutics

Lixte Biotech

Outlook Therapeutics Inc

Biotech penny stocks are heating up right now; here's 3 to watch The post Best Biotech Penny Stocks For Your Small-Caps Watchlist Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Biotech Penny Stocks For Your Small-Caps Watchlist Right Now

BRYAN, Texas, July 15, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced that preclinical studies of IBIO-202, its subunit vaccine candidate that targets the nucleocapsid protein (“N protein”) of SARS-CoV-2, demonstrated a robust, antigen-specific, memory T-cell response.

iBio Reports Successful Preclinical Immunization Studies with Next-Gen Nucleocapsid COVID-19 Vaccine Candidate

News for iBio Stock (IBIO)